Back to all companies
Sign in
Back to all companies
zPREDICTA logo

zPREDICTA

Summer 2015Acquired

Patient-derived 3D tissue reconstruction models for preclinical…

Save
zPREDICTA logo

zPREDICTA

Summer 2015Acquired

Patient-derived 3D tissue reconstruction models for preclinical…

Save
Company details

zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic.

Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications.

Location
San Francisco, CA, USA; San Jose, CA, USA
Founded
Unknown
YC Directory Pagezpredicta.com
Founder
  • MP
    Mukti Parikh
    Founder/CTO
    LinkedIn

zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic.

Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications.

Location
San Francisco, CA, USA; San Jose, CA, USA
Founded
Unknown
YC Directory Pagezpredicta.com
Founder
  • MP
    Mukti Parikh
    Founder/CTO
    LinkedIn
Pro

Upgrade to Pro, then request the zPREDICTA teardown.

This company does not have a completed analysis yet. Choose a Pro plan first, then use one of your 5 monthly research requests to have our agent investigate zPREDICTA. The full teardown, rebuild plan, and technical specs unlock when it lands.

  • Use Pro to request the first zPREDICTA teardown and keep the finished report in your account.
  • Read every completed teardown and rebuild plan already in the database.
  • Unlock implementation-ready technical specs and 5 fresh research requests each month.

Choose your Pro plan

$20/ month

Find one worth rebuilding, get the teardown, open the implementation-ready specs, and use fresh report requests when you want deeper research.

See Pro plans
Full teardown library
Specs for every company
5 fresh requests / month
CLI for agent imports
Startups.RIP — Dead startups, alive ideas
PricingContactPrivacyGot feedback? DM @oscrhong